Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares after the company reported Phase 2 data for lead asset ATH434 in patients with early-stage multiple system atrophy. The data are “mixed but overall positive,” says the analyst, who adds that the relatively small trial should inform the design of a later-stage study.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics announces ATH434 Phase 2 trial results
- Alterity Therapeutics Ltd (ADR) trading halted, news pending
- Alterity Therapeutics reports cash balance of A$4.54M as of December 31
- Alterity Therapeutics Expands ASX Quoted Securities
- Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025